INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2010

Purslane supplementation improved clinical outcomes and reduced VAS scores in patients with oral lichen planus.

A randomized double-blind placebo-controlled trial evaluated purslane versus placebo over 3 months in 37 patients with symptomatic oral lichen planus ( purslane n=20, placebo n=17). Approximately 83% of purslane patients showed partial to complete clinical improvement compared to 17% in the placebo group, with 17% of purslane patients and 73% of placebo patients showing no response. Based on VAS scores, all purslane-treated patients had partial to complete response, accompanied by a significant decrease in VAS scores at the end of the study period (p < 0.001). No serious side-effects occurred in either group.

Study type
Randomized double-blind placebo-controlled trial
Who was studied
37 biopsy-proven symptomatic oral lichen planus (OLP) patients
What was measured
Visual analog scale (VAS) score and clinical improvement (lesion type and size)

THE PAPER

Efficacy of purslane in the treatment of oral lichen planus.

Agha-Hosseini F, Borhan-Mojabi K, Monsef-Esfahani HR, Mirzaii-Dizgah I, Etemad-Moghadam S, Karagah A. Phytother Res, 2010.

PubMed 19585472 ↗DOI 10.1002/ptr.2919 ↗

Other health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.